Literature DB >> 33460452

Associations of fecal microbial profiles with breast cancer and nonmalignant breast disease in the Ghana Breast Health Study.

Doratha A Byrd1, Emily Vogtmann1, Zeni Wu1, Yongli Han1, Yunhu Wan1, Joe-Nat Clegg-Lamptey2, Joel Yarney2, Beatrice Wiafe-Addai3, Seth Wiafe4, Baffour Awuah5, Daniel Ansong5, Kofi Nyarko6, Autumn G Hullings1, Xing Hua1, Thomas Ahearn1, James J Goedert1, Jianxin Shi1, Rob Knight7, Jonine D Figueroa1,8, Louise A Brinton1, Montserrat Garcia-Closas1, Rashmi Sinha1.   

Abstract

The gut microbiota may play a role in breast cancer etiology by regulating hormonal, metabolic and immunologic pathways. We investigated associations of fecal bacteria with breast cancer and nonmalignant breast disease in a case-control study conducted in Ghana, a country with rising breast cancer incidence and mortality. To do this, we sequenced the V4 region of the 16S rRNA gene to characterize bacteria in fecal samples collected at the time of breast biopsy (N = 379 breast cancer cases, N = 102 nonmalignant breast disease cases, N = 414 population-based controls). We estimated associations of alpha diversity (observed amplicon sequence variants [ASVs], Shannon index, and Faith's phylogenetic diversity), beta diversity (Bray-Curtis and unweighted/weighted UniFrac distance), and the presence and relative abundance of select taxa with breast cancer and nonmalignant breast disease using multivariable unconditional polytomous logistic regression. All alpha diversity metrics were strongly, inversely associated with odds of breast cancer and for those in the highest relative to lowest tertile of observed ASVs, the odds ratio (95% confidence interval) was 0.21 (0.13-0.36; Ptrend < .001). Alpha diversity associations were similar for nonmalignant breast disease and breast cancer grade/molecular subtype. All beta diversity distance matrices and multiple taxa with possible estrogen-conjugating and immune-related functions were strongly associated with breast cancer (all Ps < .001). There were no statistically significant differences between breast cancer and nonmalignant breast disease cases in any microbiota metric. In conclusion, fecal bacterial characteristics were strongly and similarly associated with breast cancer and nonmalignant breast disease. Our findings provide novel insight into potential microbially-mediated mechanisms of breast disease.
© 2021 UICC.

Entities:  

Keywords:  breast cancer; microbiome; nonmalignant breast diseases

Mesh:

Substances:

Year:  2021        PMID: 33460452      PMCID: PMC8386185          DOI: 10.1002/ijc.33473

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  42 in total

1.  Testing in Microbiome-Profiling Studies with MiRKAT, the Microbiome Regression-Based Kernel Association Test.

Authors:  Ni Zhao; Jun Chen; Ian M Carroll; Tamar Ringel-Kulka; Michael P Epstein; Hua Zhou; Jin J Zhou; Yehuda Ringel; Hongzhe Li; Michael C Wu
Journal:  Am J Hum Genet       Date:  2015-05-07       Impact factor: 11.025

2.  Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study.

Authors:  James J Goedert; Gieira Jones; Xing Hua; Xia Xu; Guoqin Yu; Roberto Flores; Roni T Falk; Mitchell H Gail; Jianxin Shi; Jacques Ravel; Heather Spencer Feigelson
Journal:  J Natl Cancer Inst       Date:  2015-06-01       Impact factor: 13.506

Review 3.  Reciprocal interactions of the intestinal microbiota and immune system.

Authors:  Craig L Maynard; Charles O Elson; Robin D Hatton; Casey T Weaver
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

4.  Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa.

Authors:  Louise Brinton; Jonine Figueroa; Ernest Adjei; Daniel Ansong; Richard Biritwum; Lawrence Edusei; Kofi M Nyarko; Seth Wiafe; Joel Yarney; Beatrice Wiafe Addai; Baffour Awuah; Joe Nat Clegg-Lamptey
Journal:  Breast Cancer Res Treat       Date:  2016-12-26       Impact factor: 4.872

5.  The human tumor microbiome is composed of tumor type-specific intracellular bacteria.

Authors:  Deborah Nejman; Ilana Livyatan; Garold Fuks; Noam Shental; Ravid Straussman; Nancy Gavert; Yaara Zwang; Leore T Geller; Aviva Rotter-Maskowitz; Roi Weiser; Giuseppe Mallel; Elinor Gigi; Arnon Meltser; Gavin M Douglas; Iris Kamer; Vancheswaran Gopalakrishnan; Tali Dadosh; Smadar Levin-Zaidman; Sofia Avnet; Tehila Atlan; Zachary A Cooper; Reetakshi Arora; Alexandria P Cogdill; Md Abdul Wadud Khan; Gabriel Ologun; Yuval Bussi; Adina Weinberger; Maya Lotan-Pompan; Ofra Golani; Gili Perry; Merav Rokah; Keren Bahar-Shany; Elisa A Rozeman; Christian U Blank; Anat Ronai; Ron Shaoul; Amnon Amit; Tatiana Dorfman; Ran Kremer; Zvi R Cohen; Sagi Harnof; Tali Siegal; Einav Yehuda-Shnaidman; Einav Nili Gal-Yam; Hagit Shapira; Nicola Baldini; Morgan G I Langille; Alon Ben-Nun; Bella Kaufman; Aviram Nissan; Talia Golan; Maya Dadiani; Keren Levanon; Jair Bar; Shlomit Yust-Katz; Iris Barshack; Daniel S Peeper; Dan J Raz; Eran Segal; Jennifer A Wargo; Judith Sandbank
Journal:  Science       Date:  2020-05-29       Impact factor: 47.728

6.  Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium.

Authors:  Rashmi Sinha; Galeb Abu-Ali; Emily Vogtmann; Anthony A Fodor; Boyu Ren; Amnon Amir; Emma Schwager; Jonathan Crabtree; Siyuan Ma; Christian C Abnet; Rob Knight; Owen White; Curtis Huttenhower
Journal:  Nat Biotechnol       Date:  2017-10-02       Impact factor: 54.908

7.  Emerging breast cancer epidemic: evidence from Africa.

Authors:  Sally N Akarolo-Anthony; Temidayo O Ogundiran; Clement A Adebamowo
Journal:  Breast Cancer Res       Date:  2010-12-20       Impact factor: 6.466

Review 8.  Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions.

Authors:  Linda S Zhang; Sean S Davies
Journal:  Genome Med       Date:  2016-04-21       Impact factor: 11.117

9.  Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study.

Authors:  Christina A Clarke; Alison J Canchola; Lisa M Moy; Susan L Neuhausen; Nadia T Chung; James V Lacey; Leslie Bernstein
Journal:  Breast Cancer Res       Date:  2017-05-01       Impact factor: 6.466

View more
  5 in total

1.  The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study.

Authors:  Zeni Wu; Doratha A Byrd; Yunhu Wan; Daniel Ansong; Joe-Nat Clegg-Lamptey; Beatrice Wiafe-Addai; Lawrence Edusei; Ernest Adjei; Nicholas Titiloye; Florence Dedey; Francis Aitpillah; Joseph Oppong; Verna Vanderpuye; Ernest Osei-Bonsu; Casey L Dagnall; Kristine Jones; Amy Hutchinson; Belynda D Hicks; Thomas U Ahearn; Jianxin Shi; Rob Knight; Richard Biritwum; Joel Yarney; Seth Wiafe; Baffour Awuah; Kofi Nyarko; Jonine D Figueroa; Rashmi Sinha; Montserrat Garcia-Closas; Louise A Brinton; Emily Vogtmann
Journal:  Int J Cancer       Date:  2022-06-30       Impact factor: 7.316

2.  Exercise and Prebiotic Fiber Provide Gut Microbiota-Driven Benefit in a Survivor to Germ-Free Mouse Translational Model of Breast Cancer.

Authors:  Kara Sampsell; Weilan Wang; Christina Ohland; Lukas F Mager; Nicola Pett; Dana E Lowry; Kate M Sales; Margaret L McNeely; Kathy D McCoy; S Nicole Culos-Reed; Raylene A Reimer
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

Review 3.  The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer.

Authors:  Tünde Kovács; Edit Mikó; Gyula Ujlaki; Heba Yousef; Viktória Csontos; Karen Uray; Peter Bai
Journal:  Cancer Metastasis Rev       Date:  2021-12-30       Impact factor: 9.264

4.  Altered Gut Microbiota in Patients With Peutz-Jeghers Syndrome.

Authors:  Sui Wang; Gang Huang; Jue-Xin Wang; Lin Tian; Xiu-Li Zuo; Yan-Qing Li; Yan-Bo Yu
Journal:  Front Microbiol       Date:  2022-07-13       Impact factor: 6.064

Review 5.  The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine.

Authors:  Martina Di Modica; Valeria Arlotta; Lucia Sfondrini; Elda Tagliabue; Tiziana Triulzi
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.